Data & APIsEventsMarketfyPremarketBoost
Contribute Login Join
Data & APIs
Events
Marketfy
Premarket
Boost

Sam Backenroth Net Worth & Insider Trades

Sam Backenroth - CFO, Neubase Therapeutics, Inc

As of December 30, 2020

What is Sam Backenroth's Net Worth?

The current estimated net worth of Neubase Therapeutics, Inc's CFO, Sam Backenroth, is estimated to be about $107.26K . Sam Backenroth owns about 11,630 units of Neubase Therapeutics, Inc common stock. In the last year at Neubase Therapeutics, Inc, Sam Backenroth has sold an estimated value of $0 worth.

What is Sam Backenroth's Past Insider Trading?

Sam Backenroth's largest purchase order was 1,000 units , worth over $6K on May 4, 2020. In total, Sam Backenroth has made about 3 transactions over a year of their time at Neubase Therapeutics, Inc. Sam Backenroth usually trades in May, December and July, with the busiest year in 2020.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Sam Backenroth

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

InsideArbitrage

Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What is Sam Backenroth's' Mailing Address?

  • Mailing address is 489 5th Ave., 28th Floor New York NY 10017 NY

What are Neubase Therapeutics, Inc's Past Insider Trades?

Neubase Therapeutics, Inc's most recent insider trade came on September 18, 2023 by Symetryx Corp who sold 282,445 units worth $375.62K . In the last 3 years, insiders at Neubase Therapeutics, Inc have sold an estimated value of $712.35K and bought an estimated value of $551.58K worth of shares. Insider trading is most common in September, with the busiest year in 2022. The most active traders at the company are Dietrich Stephan, Founder and CEO,  Dov A. Goldstein, Director,  and Eric I Richman, Director .

NeuBase Therapeutics, Inc. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...